Arca
Skip to content
Tools
Tools

Thrombosis

Drug research and approvals for thrombosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 437 studies of thrombosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 19 drug trials for it since 2013, FDA has 3 approved and 5 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 437
  • Trials authorized in Canada: 19
  • FDA orphan approvals: 3
  • EU medicines: 3

Recruiting now

Newest posted first, of 437 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 52

Phase 3 12 of 23

Phase 2 12 of 16

Phase 1 or earlier 11

How its trials ended

1,532 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 316 whose ending is known, 44% met their primary endpoint, 10% missed it and 46% stopped early.

  • Completed, result not reported63842%
  • Ongoing29920%
  • Status unknown27918%
  • Met its primary endpoint1399%
  • Stopped: other or unclear775%
  • Stopped: enrollment or feasibility362%
  • Missed its primary endpoint322%
  • Stopped: funding101%
  • Stopped: lack of efficacy81%
  • Stopped: sponsor or business decision81%
  • Stopped: safety6<1%

Trials authorized in Canada

The 10 newest of 19; search them all in Canada trials
Sep 25, 2026Open-label, multi-center, single-dose phase 1 study to investigate the pharmacokinetics, safety, and tolerability of milvexian in pediatric patients from 28…Milvexian (BMS-986177, JNJ-70033093)Johnson & JohnsonPending
Jul 30, 2026A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of REGN7508, a monoclonal antibody against fxi, for…REGN7508RegeneronPending
Aug 13, 2025Avoiding risks of thrombosis and bleeding in surgery (ARTS): an international randomized controlled trial evaluating apixaban versus no anticoagulation in…ApixabanDr. Kari TikkinenOngoing
Feb 20, 2025A pilot randomized double-blinded comparison of full treatment dose rivaroxaban for 90 days to prophylactic dose rivaroxaban for 45 days in patients with lower…RivaroxabanOttawa Hospital Research InstituteOngoing
May 7, 2024The impact of additional post-operative doses of tranexamic acid on pain, mobility and bleeding following total hip and total knee arthroplasty: a randomized…Tranexamic acidST MARY's RESEARCH CENTREOngoing
May 2, 2024A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of bay 3018250 in patients with symptomatic proximal deep…Bay 3018250BayerClosed
May 2, 2024Colchicine to quench the inflammatory response after deep vein thrombosis: a randomized controlled pilot trial (the conquer-dvt pilot trial)ColchicineOttawa Hospital Research InstituteOngoing
Dec 24, 2020A randomized controlled trial on the use of postoperative extended venous thromboprophylaxis in patients with inflammatory bowel disease. a pilot studyApixabanMcMaster UniversityOngoing
Jun 25, 2020Factor xi lica to reduce thrombotic events in end-stage renal disease patients on hemodialysis: a phase 2, randomized, double-blind, placebo-controlled study…Bay 2976217BayerClosed
Jun 18, 2020Long-term treatment of cancer associated vte: reduced vs full dose of apixaban : api-cat study for apixaban cancer associated thrombosisApixabanAssistance Publique - Hôpitaux De ParisClosed

FDA orphan designations

Approved first, then open designations, newest first
Mar 30, 2007CeprotinPrevention and treatment of venous thrombosis and purpura fulminansBaxalta US, Inc.Approved
Mar 14, 1997AgrylinTreatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate…Takeda Development Center Americas, Inc.Approved
Dec 30, 1991Thrombate IIIFor replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.Bayer CorporationApproved
Apr 8, 2024TecarfarinPrevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist…Cadrenal TherapeuticsDesignated
Dec 30, 2020N-Benzothiazol-2-yl-4-(2-hydroxy-3-methoxy-benzylamino)-beze…Prophylaxis of thrombosis in patients with heparin-induced thrombocytopeniaCadrenal Therapeutics, Inc.Designated
Nov 2, 2005BivalirudinFor use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis…The Medicines CompanyDesignated
Jun 18, 2001Reviparin sodiumTreatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patientsAbbottDesignated
Jan 2, 1986Antithrombin III humanPreventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis…American National Red CrossDesignated

Medicines authorised in the EU

Newest first
Nov 21, 2025Svariya (previously Rivaroxaban Koanaa)Rivaroxaban · genericPGF Pharma International d.o.o.EMA ↗
Nov 16, 2020Rivaroxaban AccordRivaroxaban · genericAccord Healthcare S.L.U.EMA ↗
Mar 20, 2002ArixtraFondaparinux sodiumViatris Healthcare LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.